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The identification of specific HLA risk alleles in drug- induced liver injury (DILI) points toward an important role of the 
adaptive immune system in DILI development. In this study, we aimed to corroborate the role of an adaptive immune 
response in DILI through immunophenotyping of leukocyte populations and immune checkpoint expressions. Blood 
samples were collected from adjudicated DILI (n = 12), acute viral hepatitis (VH; n = 13), acute autoimmune hepatitis 
(AIH; n = 9), and acute liver injury of unknown etiology (n = 15) at day 1 (recognition), day 7, and day >30. Blood 
samples from patients with nonalcoholic fatty liver disease (NAFLD; n = 20) and healthy liver controls (HLCs; n = 54) 
were extracted at one time point. Leukocyte populations and immune checkpoint expressions were determined 
based on cell surface receptors, except for CTLA- 4 that was determined intracellularly, using flow cytometry. At 
recognition, DILI demonstrated significantly higher levels of activated helper T- cell (P < 0.0001), activated cytotoxic 
T- cells (P = 0.0003), Th1 (P = 0.0358), intracellular CTLA- 4 level in helper T- cells (P = 0.0192), and PD- L1 presenting 
monocytes (P = 0.0452) than HLC. These levels approached those of HLC over time. No significant differences were 
found between DILI and VH. However, DILI presented higher level of activated helper T- cells and CTLA- 4 than NAFLD 
and lower PD- L1 level than AIH. Our findings suggest that an adaptive immune response is involved in DILI in which 
activated CD4+ and CD8+ play an important role. Increased expression of negative immune checkpoints is likely the 
effect of peripheral tolerance regulation.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 The underlying mechanism of drug- induced liver injury 
(DILI) is not yet fully elucidated. However, the identification 
of HLA risk alleles in DILI suggests an important role for the 
adaptive immune system.
WHAT QUESTION DID THIS STUDY ADDRESS?
 We compared immune activation status in DILI and other 
acute and chronic liver conditions by determining lymphocyte 
populations and immune checkpoint levels by flow cytometry 
in serial blood samples from patients and controls.
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
 Activation of helper and cytotoxic T- cells is increased at 
DILI onset similar to acute viral hepatitis. However, DILI 
presented higher level of activated helper T- cells and CTLA- 4 
than nonalcoholic fatty liver disease and lower PD- L1 level 
than autoimmune hepatitis. This further supports the involve-
ment of an adaptive immune response in DILI development. 
However, no specific “immune fingerprint” was detected that 
could distinguish DILI from other forms of liver injury.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 Defining the cellular mechanism in DILI facilitates specific 
biomarker development for DILI diagnosis and prognosis. Such 
biomarkers would enable faster and more reliable DILI manage-
ment in clinical practice.
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Idiosyncratic drug- induced liver injury (DILI) is a rare but im-
portant condition, which can potentially cause acute liver fail-
ure leading to death or liver transplantation. It is also one of 
the main reasons behind postmarketing drug withdrawals and 
is consequently of importance for the pharmaceutical industry. 
The development of DILI is considered to be multifactorial, and 
dependent on a combination of drug properties, host factors, as 
well as environmental factors.1 The immune system is believed to 
play a fundamental role in DILI development and progression.2 
This is supported by findings of specific human leukocyte anti-
gen (HLA) alleles associated with DILI susceptibility to specific 
drugs.3 Intermediate metabolites formed during drug metabo-
lism may act as haptens and bind to endogenous proteins to form 
adducts that when presented on specific HLA molecules as neo-
antigens may trigger T- cell activation and an immune response. 
However, the liver is constantly exposed to foreign antigens and 
bacterial matters from the endogenous microbiota due to being a 
highly vascularized organ in which ~ 25– 30% of the body’s blood 
supply passes through every minute.4 A large proportion of this 
comes via the portal vein from the gastrointestinal tract. To pro-
tect itself from chronic inflammation, the liver has a propensity for 
immune tolerance. The development of DILI is therefore believed 
to depend on an interruption of the liver’s tolerogenic state.5 In 
fact, many liver conditions have been associated with alterations in 
immune tolerance, such as autoimmune hepatitis, primary biliary 
cirrhosis, and primary sclerosing cholangitis.6– 8
In addition to antigen presentation on HLA molecules, the gen-
eration of T- cell activation is likewise dependent on further signals 
from stimulatory and inhibitory immune checkpoints binding to 
their corresponding ligands (Figure 1). CD28 is the most important 
costimulatory membrane receptor for T- cell activation. It is consti-
tutively expressed on resting and activated T- cells and binds to the 
B7- 1 (CD80) and B7- 2 (CD86) ligands present on antigen present-
ing cells (APCs). Another costimulatory receptor is ICOS (CD278), 
which when bound to its ligand ICOS- L (CD275) provides stimu-
latory signals for T- cell activation. It differs from CD28 in that it is 
an inducible receptor and its effect appears less potent than that of 
CD28. Nevertheless, ICOS co- stimulation is believed to play a com-
plex role in dictating the course of adaptive immunity and is a critical 
component in the production of isotype- switched antibodies.9
In addition to positive co- stimulation, CTLA- 4 (CD152) 
and PD- 1 (CD279) exert inhibitory effects on T- cell activation. 
CTLA- 4 is a direct antagonist of CD28 stimulation as it competes 
for the same ligands (B7- 1 and B7- 2), which it binds to with higher 
affinity than CD28. In contrast to CD28, CTLA- 4 is only expressed 
on activated T- cells. This receptor is characterized by rapid endo-
cytosis from the plasma membrane resulting in most of CTLA- 4 
being intracellular. Although both CTLA- 4 and PD- 1 provide in-
hibitory signals, CTLA- 4 seems to be important for limiting T- cell 
activity at an earlier phase of T- cell activation, whereas the inhibi-
tory effect of PD- 1 when bound to its ligand PD- L1 (CD274) oc-
curs later and limits T- cell activity in peripheral tissues.10
Variations in peripheral leukocyte populations can occur during 
disease development as different leukocyte populations are re-
cruited to specific tissues and organs, including the liver, during 
injury and infections. The goal of these migrating populations is to 
eliminate the inflammatory trigger and facilitate tissue repair, and 
is associated with both innate and adaptive immune responses.11 
The rate of leukocyte recruitment and the nature of the recruited 
cells in response to inflammatory signals will shape the severity of 
the conditions.12
In this study, we aimed to determine the immunological finger-
print of DILI through flow cytometry analysis of peripheral blood 
and compare that to those of other hepatic conditions and popu-
lation controls without liver injury. We also set out to determine 
the level of leukocytes presenting immune checkpoint receptors 
and their corresponding ligands to corroborate that an adaptive 
immune response is fundamental in DILI development.
Figure 1 Schematic presentation of immune checkpoint receptors and their corresponding ligands. Antigens bound to the human leukocyte 
antigen (HLA) molecules on antigen presenting cells are recognized by T- cell receptors on T- cell lymphocytes. The checkpoint receptors 
CD28 and ICOS (CD278) when bound to their ligands CD80/CD86 and ICOS- L (CD275) provide a costimulatory signal for T- cell activation. In 
contrast, CTLA- 4 (CD152) and PD- 1 (CD279) bind to the CD80/86 and PD- L1 ligands to exert an inhibitory signal, which limits T- cell activation.
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MATERIALS AND METHODS
Subjects and study protocol
Acute idiosyncratic DILI cases were obtained from those submitted to 
the Spanish DILI Registry; a collaborative network established in 1994 
to prospectively identify cases of DILI in a standardized manner. All 
patients with DILI fulfilled at least one of the following 3 biochemical 
DILI criteria at the time of study recruitment: (i) alanine aminotrans-
ferase (ALT) ≥ 5 times the upper limit of normal (ULN), (ii) ALT ≥ 3 
times the ULN + total bilirubin (TBL) ≥  2 times the ULN, and (iii) 
alkaline phosphatase (ALP) ≥ 2 times the ULN.13 Most cases fulfilled 
one of the ALT- based criteria. Only three cases met the ALP- based 
criterion alone without fulfilling either of the two ALT- based crite-
ria. Serological and biochemical tests were performed to rule out liver 
damage from viral hepatitis (hepatitis A virus (HAV), hepatitis B virus 
(HBV), hepatitis C virus (HCV), hepatitis E virus (HEV), cytomegalo-
virus (CMV), and Epstein- Barr virus (EBV)) and imaging tests to rule 
out bile duct disorders. Alternative causes of liver injury, such as auto-
immune hepatitis, were also ruled out. All submitted cases were evalu-
ated for causality assessment, initially by clinical assessment and later by 
applying the Roussel Uclaf Causality Assessment Method (RUCAM), 
also known as the “Council for International Organizations of Medical 
Science (CIOMS) scale.” The acute liver injury control groups viral hepa-
titis (VH), autoimmune hepatitis (AIH), and unknown etiology (UKE) 
used in this study met the same biochemical inclusion criteria as the 
DILI cases, whereas the patients with chronic non- alcoholic fatty liver 
disease (NAFLD), with lower liver profile elevations, were identified 
based on detection of steatosis in liver biopsies and/or abdominal ultra-
sound examinations. The VH group consisted of patients infected with 
HAV (46%), HBV (23%), HCV (7.7%), HEV (7.7%), CMV (7.7%), and 
EBV (7.7%). The UKE group consisted of acute liver injury cases that 
were initially suspected to be DILI, but could not be diagnosed as DILI 
with sufficient certainty based on the available information. Healthy 
liver controls (HLCs) presented a normal liver profile at the time of 
sample collection and had previously not suffered from any known DILI 
episode. This group was formed of university employee volunteers who 
underwent their yearly medical examination at the Área de medicina 
del trabajo de la Universidad de Málaga at Malaga University. The study 
protocol was approved by the local Ethics Committee at the Virgen de 
la Victoria University Hospital in Málaga, Spain, and all subjects gave 
informed consent.
Sample collection and preparation
Serial blood samples were prospectively collected from patients with 
DILI, VH, AIH, and UKE at days 1, 7, and ≥ 30 from liver injury de-
tection. In the case of patients with NAFLD and HLC, blood samples 
were extracted at a single visit. After extraction, blood samples were 
immediately stained with combinations of monoclonal antibodies con-
jugated with specific fluorophores (Table S1) and incubated for 30 min-
utes in darkness at room temperature. Samples were subsequently treated 
with lysing buffer (Becton Dickinson, Franklin Lakes, NJ) to remove 
erythrocytes, and finally washed and suspended in phosphate- buffered 
saline buffer prior to flow cytometry measurements. Due to difficulties 
in detecting cells presenting extracellular CD152 membrane receptors, 
the presence of CD152 was determined intracellularly. Hence, cells were 
treated with permeabilizing solution (Becton Dickinson) according to 
the manufacturer’s instructions prior to monoclonal antibody staining, 
similar to Matsubara et al.14
Multicolor flow cytometry
Multicolor flow cytometry was performed using a BD FACSVerse 
Universal Loader cytometer. Measurement data were collected and an-
alyzed using the Kaluza Flow Cytometry Analysis Software (Beckman 
Coulter, Indianapolis, IN). Gatings were performed based on size and 
complexity to select and identify specific lymphocyte and monocyte 
populations. The different leukocyte populations were detected based 
on the expression of specific membrane receptors as outlined in Table 1.
Statistics
Sizes of the different leukocyte populations were compared between 
patient and control groups using nonparametric Kruskal- Wallis tests 
followed by post hoc analyses using Mann- Whitney tests. All statis-
tical tests were 2- sided hypotheses performed at the 0.05 level of sig-
nificance. Due to the exploratory nature of the study, the presented P 
values are not corrected and we considered a type I error (α) of 0.05 to 
reject the hypothesis testing.15 The statistical analyses were performed 




In this study, we analyzed serial blood samples from 12 patients 
with DILI, 13 with VH, 9 with AIH, and 15 with UKE and a 
single blood sample from 20 patients with NAFLD. In addi-
tion, 54 HLCs without any liver conditions were included as 
a control group for comparison. Table  2 shows demographics 
Table 1 Combination of markers used to analyze different 
lymphocyte populations
Lymphocyte populations








B cells CD4- /CD20 + /CD45+









CTLA- 4 (CD152)+a CD4+/CD152+
ICOS (CD278)+ CD4+/CD278+




ICOS- L (CD275)+ CD11b/Mac- 1+/CD275+
PD- 1L (CD274)+ CD11b/Mac- 1+/CD274+
Markers used to analyze cells expressing immune checkpoint receptors and 
ligands in both lymphocytes and monocytes are also indicated.
 aIntracellularly after permeabilization.
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and clinical characteristics of the study populations. The mean 
age varied from 44 years for the VH group to 58 years for the 
AIH group. Women predominated among patients with DILI, 
AIH, and HLC, while men were more frequent among patients 
with VH, NAFLD, and UKE. Of the patients with DILI, 83% 
developed DILI due to conventional medications and 17% oc-
curred due to use of herbal and dietary supplements. A detailed 
description of the causative agents and corresponding HLA 
risk alleles identified to date can be found in Table S2. With 
regard to liver profile elevations, substantial ALT elevations 
were apparent in the VH, AIH, and UKE groups, somewhat 
lower in the DILI group and relatively low in the NAFLD 
group. Similarly, substantial TBL elevations were detected in 
the AIH and UKE groups, whereas those of the patients with 
DILI and VH were lower but substantially higher than those 
of the patients with NAFLD. Of the patients with NAFLD, 
33% were considered to have a fibrosis stage F0, 13% were stage 
F1, 6.7% were stage F2, 20% were stage F3, and 27% were stage 
F4. The highest proportion of death/liver transplantation cases 
occurred among the AIH cases followed by UKE, DILI, and 
VH (Table 2).
Variations in leukocyte populations
Significant differences in leukocyte (P  =  0.0047), neutrophil 
(P = 0.004), and monocyte (P < 0.0001) counts, but not lympho-
cyte counts, were detected among the groups (Table 3). However, 
the DILI group only differed from the HLCs (P  =  0.037) and 
AIH (P = 0.023) in monocyte count and from AIH (P = 0.0404) 
in leukocyte count. The most noticeable cohort was that of AIH, 
which had significantly higher leukocyte (P = 0.0027), neutrophil 
(P = 0.0006), and monocyte (P < 0.0001) counts than those of 
HLCs.
We compared the proportion of specific lymphocyte popula-
tions between different liver injury groups and HLCs using flow 
cytometry, and evaluated the presence of specific immune check-
point receptors and ligands on both lymphocytes and monocytes 
in the different groups (Figure 2). Table 3 presents mean percent-
ages for each of the cell populations in the different study groups 
at day 1. Similar proportions of helper T- cells were found at day 
1 in the study groups. However, differences were detected in the 
proportion of activated helper T- cells (P  =  0.0003), with DILI 
presenting a significantly higher proportion than HLCs (14% vs. 
6.3%, P  <  0.0001) and NAFLD (14% vs. 8.2%, P  =  0.0150). In 
Table 2 Comparison of demographics and clinical characteristics between patients with DILI, acute VH, acute AIH, UKE, 
NAFLD, and HLCs
DILI   
N = 12








HLCs   
N = 54
Age (y), mean ± SD 55 ± 15 44 ± 20 57 ± 19 55 ± 24 53 ± 13 50 ± 11
Female, % 58 31 67 40 40 59
BMI (kg/m2), mean ± SD 23.8 ± 5.6 24.5 ± 4.0 26.9 ± 5.2 24.9 ± 2.8 30.4 ± 3.8 24.6 ± 4.3
Diabetes mellitus, % 17 23 0 13 N/D 3.8
Hypertension, % 25 15 33 33 N/D 19
Liver episode characteristics, %
Jaundice 58 62 100 67 0 N/A
Hospitalization 67 77 100 87 0 N/A
Type of liver injury, %
Hep 55 62 100 53 N/A N/A
Chol 36 15 0 20 N/A N/A
Mix 9.1 23 0 27 N/A N/A
Laboratory parameters at visit 1
TBL, mg/dL (range) 6.3 (0.3– 21) 7.4 (0.4– 19) 17 (7.3– 34) 9.5 (0.3– 28) 0.7 (0.3– 1.2) 0.6 (0.2– 0.8)
AST, IU/L (range) 240 (41– 656) 671 (79– 2697) 846 (122– 1875) 638 (15– 2154) 48 (20– 77) 24 (9– 29)
ALT, IU/L (range) 417 (37– 1213) 1279 (115– 5162) 906 (217– 2273) 783 (50– 2257) 79 (24– 205) 22 (15– 27)
ALP, IU/L (range) 257 (93– 768) 240 (92– 509) 233 (103– 309) 237 (96– 555) 88 (40– 194) 59 (30– 89)
Severity, %
Mild 33 7.7 0 13 N/A N/A
Moderate 58 85 67 60 N/A N/A
Severe 0 0 11 6.7 N/A N/A
Death/liver 
transplantation
8.3 7.7 22 20 N/A N/A
AIH, autoimmune hepatitis; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; Chol, 
cholestatic; DILI, drug- induced liver injury; Hep, hepatocellular; HLCs, healthy liver controls; Mix, mixed; N/A, not applicable; NAFLD, non- alcoholic fatty liver 
disease; TBL, total bilirubin; UKE, unknown etiology; VH, viral hepatitis.
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addition, VH (14% vs. 6.3%, P = 0.0031) and NAFLD (8.2% vs. 
6.3%, P = 0.031) also presented significantly higher activated helper 
T- cells than HLCs. Only VH differed significantly from HLCs 
(29% vs. 21%, P = 0.001) in cytotoxic T- cell proportion. In con-
trast, several groups presented an increased level of activated cyto-
toxic T- cells compared with HLCs, including DILI (31% vs. 15%, 
P = 0.0003), VH (39% vs. 15%, P < 0.0001), and AIH (32% vs. 
15%, P = 0.0105). With regard to helper T- cell subpopulations, the 
distributions of Th1 (P = 0.0311) and Th9 (P = 0.0026) cells dif-
fered significantly. Increased level of Th1 cells was detected in DILI 
(52% vs. 42%, P = 0.0358) and NAFLD (53% vs. 42%, P = 0.0062) 
compared with HLCs. The NAFLD group also demonstrated in-
creased level of Th9 (25% vs. 18%, P = 0.0267), whereas the UKE 
and VH groups presented lower levels than HLCs (13% vs. 18%, 
P = 0.0159 and 13% vs. 18%, P = 0.0112, respectively).
Variations were also found in the proportion of B cells, but 
only UKE differed significantly from HLCs (6.5% vs. 9.8%, 
P  =  0.0014). No significant differences were found between the 
different study groups for any of the other lymphocyte popula-
tions. The detected variations in the aforementioned leukocyte 
populations approached HLC levels in the subsequent visits at 
days 7 and ≥ 30, as illustrated in Figure 3, with the exception of 
Table 3 Absolute count and percentage of leukocyte populations in peripheral blood samples from patients with DILI, acute 













Cell count, mean (×109/L) ± SD
Leukocytes 6.5 ± 3.0 7.0 ± 2.9 9.2a,b ± 3.2 8.9a ± 6.6 ND 5.9 ± 1.8 0.0054
Lymphocytes 1.6 ± 0.7 2.3 ± 1.7 1.5 ± 0.5 1.8 ± 1.1 ND 1.8 ± 0.7 0.4295
Neutrophils 4.2 ± 2.2 3.7 ± 2.2 6.5a ± 2.9 6.1a ± 6.5 ND 3.4 ± 1.4 0.004
Monocytes 0.6a ± 0.3 1.4a ± 2.1 1.0a,b ± 0.3 0.8a ± 0.4 ND 0.4 ± 0.1 < 0.0001
Lymphocyte populations
Helper T- cell (% CD45) 43 ± 11 42 ± 13 44 ± 6.0 43 ± 11 43 ± 8.6 46 ± 7.2 0.8247
Naive (% CD4) 25 ± 13 40 ± 13 31 ± 12 33 ± 16 27 ± 12 35 ± 13 0.0719
Memory (% CD4) 71 ± 12 58 ± 14 66 ± 11 65 ± 16 70 ± 12 63 ± 13 0.2851
Activated (% CD4) 14a ± 8.8 14a ± 8.2 9.8 ± 4.6 9.5 ± 7.5 8.2a,b ± 3.7 6.3 ± 3.1 0.0003
Cytotoxic T- cells (% CD45) 24 ± 9.9 29a ± 9.6 22 ± 7.4 25 ± 10 19 ± 7.1 21 ± 5.5 0.0277
Naive (% CD8) 17 ± 9.7 25 ± 19 21 ± 12 18 ± 16 23 ± 12 29 ± 16 0.1015
Memory (% CD8) 49 ± 12 57 ± 19 53 ± 15 49 ± 9 48 ± 14 46 ± 16 0.6656
Activated (% CD8) 31a ± 14 39a ± 24 32a ± 17 27 ± 21 22 ± 15 15 ± 10 0.0002
Regulatory T- cells (% CD4) 8.0 ± 1.9 8.1 ± 2.4 9.0 ± 3.0 8.9 ± 2.9 7.1 ± 2.2 7.2 ± 1.9 0.1275
Th1 (% CD4) 52a ± 13 44 ± 11 44 ± 7.9 41 ± 13 53a ± 14 42 ± 11 0.0311
Th2 (% CD4) 9.5 ± 4.0 14 ± 5.4 12 ± 6.5 13 ± 5.3 11 ± 4.4 12 ± 4.9 0.3997
Th9 (% CD4) 20 ± 7.5 13a ± 6.1 19 ± 7.1 13a ± 5.1 25a ± 11 18 ± 5.5 0.0026
Th17 (% CD4) 13 ± 5.6 14 ± 5.3 19 ± 9.5 14 ± 4.9 16 ± 6.6 13 ± 4.4 0.5051
Th22 (% CD4) 3.2 ± 1.6 3.3 ± 2.2 4.4 ± 2.8 4.3 ± 2.4 4.0 ± 1.4 4.4 ± 1.8 0.4178
B cells (% CD45) 11 ± 6.8 7.7 ± 3.6 11 ± 7.0 6.5a ± 4.8 11 ± 4.6 9.8 ± 4.3 0.0197
NK cells (% CD45) 14 ± 11 8.8 ± 6.6 9.6 ± 3.9 12 ± 6.2 12 ± 5.4 12 ± 5.9 0.2834
NKT- cells (% CD45) 0.5 ± 0.5 1.4 ± 1.5 0.6 ± 0.3 0.6 ± 1.0 0.5 ± 0.8 0.6 ± 0.8 0.1585
CD28+ (% CD4) 91 ± 9.3 91 ± 8.0 92 ± 5.4 93 ± 11 96 ± 5.9 96 ± 4.8 0.2230
ICOS+ (% CD4) 5.1 ± 4.2 8.7a ± 5.7 3.9a ± 1.1 2.7 ± 1.8 1.8 ± 0.7 2.3 ± 0.9 < 0.0001
CTLA- 4+ (% CD4) 28a ± 8.0 30a ± 15 38a ± 8.7 24a ± 11 18b ± 4.6 18 ± 6.2 < 0.0001
PD- 1+ (% CD4) 13 ± 8.5 23a ± 11 15 ± 7.2 12 ± 7.7 10 ± 5.9 9.3 ± 5.2 0.0131
Monocyte populations
CD80+ (% CD11b) 7.9 ± 3.3 10 ± 6.3 12 ± 8.6 13 ± 8.5 10 ± 5.8 9.2 ± 4.4 0.6693
CD86+ (% CD11b) 9.5 ± 5.1 9.5 ± 2.3 9.1 ± 5.3 11 ± 3.9 12 ± 3.5 11 ± 3.5 0.2561
ICOS- L+ (% CD11b) 15 ± 6.2 15 ± 6.8 12 ± 8.6 15 ± 7.4 16 ± 3.9 13 ± 4.2 0.0797
PD- L1+ (% CD11b) 5.3a ± 1.8 9.1a ± 4.4 10a,b ± 5.2 8.1a ± 5.6 5.0a ± 1.3 3.9 ± 1.8 < 0.0001
AIH, autoimmune hepatitis; DILI, drug- induced liver injury; HLCs, healthy liver controls; NAFLD, non- alcoholic fatty liver disease; UKE, unknown etiology; VH, viral 
hepatitis.
Statistical tests: Kruskal- Wallis test followed by post hoc analyses using Mann- Whitney U test.
 aSignificantly different from HLCs (P < 0.05).
 bsignificantly different from DILI (P < 0.05).
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Th1 cells in DILI for which the mean decrease was less apparent 
in the last visit. Nevertheless, the difference between Th1 cells in 
DILI in the last visit and that of HLCs was no longer statistically 
significant.
Variations in immune checkpoints
We also determined the level of immune checkpoint receptors and 
ligands on helper T- cells and activated monocytes, respectively, to 
demonstrate the presence of a possible adaptive immune response 
(Table  3). Regarding the costimulatory immune checkpoints, 
no differences were detected between any of the patient groups 
and HLCs for CD28+ cells, which is consistent with this recep-
tor being constitutively expressed. However, significantly higher 
levels of ICOS+ T- cells were detected in VH (8.7% vs. 2.3%, 
P < 0.0001) and AIH (3.9% vs. 2.3%, P = 0.0001). The level of 
ICOS+ T- cells in DILI was higher than HLCs (5.1% vs. 2.3%), 
but did not reach statistical significance. With regard to inhibi-
tory immune checkpoints, we found that the intracellular level of 
CTLA- 4 differed among the study groups (P < 0.0001). The level 
of CTLA- 4 was significantly higher in DILI than HLCs (28% 
vs. 18%, P  =  0.0192) and NAFLD (28% vs. 18%, P  =  0.0227). 
Similarly, VH (30% vs. 18%, P  =  0.0068), AIH (38% vs. 18%, 
P < 0.0001), and UKE (24% vs. 18%, P = 0.0120) demonstrated 
an increased level of CTLA- 4 compared with HLCs. No signifi-
cant difference was detected in the level of the additional inhib-
itory checkpoint receptor PD- 1 between DILI and HLCs. Only 
VH presented significantly higher PD- 1 level than HLCs (23% vs. 
9.3%, P = 0.0005).
In terms of immune checkpoint ligands situated on activated 
monocytes, only the level of PD- L1 differed between the groups 
(P < 0.0001). All subgroups presented a higher level of PD- L1 
expression than HLCs (DILI: 5.3% vs. 3.9%, P = 0.0452; VH: 
9.1% vs. 3.9%, P  <  0.0001; AIH: 10% vs. 3.9%, P  =  0.0004; 
UKE: 8.1% vs. 3.9%, P < 0.0001; and NAFLD: 5.0% vs. 3.9%, 
P  =  0.0104). In addition, the increased expression in AIH was 
borderline significant compared with DILI (10% vs. 5.3%, 
P = 0.0418).
To investigate any potential effect resulting from phenotype 
variations, the leukocyte population and immune checkpoint data 
were re- analyzed after removing three cases (one DILI and two 
UKE) which at the time of detection presented ALP > 2 times the 
ULN and whose ALT level did not exceed 5 times the ULN (or 
alternatively 3 times the ULN in the presence of TBL > 2 times 
the ULN) at any timepoint during the episode. No substantial dif-
ferences were detected between the results obtained when using 
the original and the reduced cohort. The main findings associated 
with DILI remained when cases only fulfilling the ALP- based cri-
terion were removed (Table S3).
A spearman analysis was performed between quantitative vari-
ables (lymphocyte/checkpoint populations and biochemical 
variables) in search for immunological factors associated with the 
degree of liver injury. However, the limited number of patients 
in the study cohorts prevented any firm conclusions to be drawn 
(data not shown).
DISCUSSION
Flow cytometry enables the characterization of lymphocyte pop-
ulations (immunophenotyping) in complex cell mixtures, such as 
peripheral blood. Given that lymphocyte infiltration into the liver 
occurs during many diseases, immunophenotyping of peripheral 
blood could reflect immune- related changes associated with a 
specific condition. In our study, we analyzed general lympho-
cyte populations (major functional lymphocyte cell subsets) and 
the expression of cellular markers involved in immune response 
regulation (immune checkpoint expressions) in DILI compared 
with non- drug- induced liver conditions and healthy controls, to 
support the involvement of an adaptive immune response in DILI 
development. The proportion of activated helper T- cells (CD4+/
HLA- DR+) and activated cytotoxic T- cells (CD8+/HLA- DR+) 
were both significantly increased at an early stage in DILI, and 
Figure 2 Flow cytometry results in a representative drug- induced liver injury (DILI) and healthy liver control (HLC) case of leukocyte populations 
(activated helper T- cells, activated cytotoxic T- cells, Th1, CTLA- 4 presenting helper T- cells, and PD- 1L presenting monocytes) found to be 
significantly higher in the DILI cohort. [Colour figure can be viewed at wileyonlinelibrary.com]
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Figure 3 Longitudinal study of leukocyte populations with significant differences in peripheral blood of patients with drug- induced liver injury 
(DILI), acute viral hepatitis (VH), acute autoimmune hepatitis (AIH), and acute liver injury of unknown etiology (UKE). The median is represented 
as the horizontal line within the box and the mean as the + sign. The top and the bottom of the box represent the 75th and 25th percentiles, 
respectively.
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even more so in viral hepatitis compared to HLCs. Unlike other 
activation markers, HLA- DR is considered a late activation 
marker.16 This suggests initiation of T- cell activation in DILI 
prior to disease detection and is in line with an adaptive immune 
response. HLA- DR molecules are constitutively expressed on B 
cells and antigen- presenting cells, but are also known to occur on 
activated T- cells.17 In addition, HLA- DR expression has also been 
observed on different regulatory T- cell (Treg) subpopulations 
with suppressive activity, which is important in maintaining self- 
tolerance and preventing autoimmunity.18 Although presence of 
HLA- DR on Treg cells was not determined in the current study, it 
is unlikely that the significant increase in CD4+/HLA- DR+ cells 
found corresponds to immune suppressive Treg cells as the level of 
Treg cells did not differ from that of HLCs. In addition, the levels 
of CD4+/HLA- DR+ cells were notably higher than the propor-
tion of Tregs. This points toward an active role for both CD4+ 
and CD8+ T- cells in DILI development, and is in accordance 
with earlier findings from cell- based assays.19,20 Surprisingly, we 
also detected an increase in Th1 cells, a lineage of CD4+ effector 
T- cells, in DILI, which was higher than that of VH. The reason 
for this is unclear, but could include differences in cytokine release 
between the two conditions and subsequent T- cell polarization.
One might hypothesize that the tendency toward lower lym-
phocyte count and level of T- cell activation in DILI compared 
with VH (although not reaching statistical significance) could in-
dicate that the T- cell response in DILI is oligoclonal, whereas viral 
infections with various immunogenic antigens usually result in a 
polyclonal T- cell response. If the causative drug forms a neoantigen 
through haptenization with a unique endogenous peptide, a mono-
clonal/oligoclonal T- cell response is likely to occur. However, no 
information on T- cell receptor Vbeta repertoires implicated in 
DILI is currently available.
An increased proportion of helper T- cells expressing the costim-
ulatory checkpoint receptor ICOS was also seen in DILI, although 
the increase was not statistically significant. ICOS is weakly ex-
pressed on naïve T- cells and quickly upregulated on activated 
helper and cytotoxic T- cells.9 Hence, increased level of ICOS in 
DILI is in line with T- cell activation and an adaptive immune re-
sponse, similar to the occurrence in the VH group.
Increased PD- L1 expression on monocytes were detected in all pa-
tient groups including DILI, whereas increased PD- 1 expression on 
T- cells were most evident in patients with VH. PD- 1 is upregulated 
during the symptomatic phase in acute viral hepatitis and downreg-
ulated after recovery.21 Transient upregulation of PD- 1 and PD- L1 
also occurs during other forms of acute infections and is thought to 
be a way of regulating peripheral tolerance.22 This could similarly be 
the case in DILI. Increased PD- 1 expression is also associated with 
T- cell exhaustion (impaired proliferation and effector function), but 
this occurs generally during persistent infection/inflammation. The 
decreasing levels of PD- 1 over time in the current study points to-
ward peripheral tolerance regulation rather than T- cell exhaustion.
The checkpoint receptor CTLA- 4 was quantified intracellularly 
as it undergoes rapid internalization. In fact, Qureshi et al. demon-
strated that 80% of membrane bound CTLA- 4 was internalized 
within 5 minutes and that this process does not change during T- cell 
activation, as initially believed.23 Nevertheless, increased transient 
cell surface expression of CTLA- 4 is known to occur on CD4+ 
T- cells during the early phase of T- cell responses. The increase in 
intracellular CTLA- 4 detected in DILI (as well as VH, AIH, and 
UKE) could therefore reflect the accumulation of CTLA- 4 expres-
sion since the initiation of the immune response, assuming that re-
ceptor expression is superior to intracellular degradation.24 Hence, 
the observed reduction in intracellular CTLA- 4 over time as the 
patient recuperates from the liver episode may reflect the reduction 
in antigen presentation and subsequent T- cell activation, based on 
findings from in vitro studies of T- cell receptor stimulation.25
This study has revealed new information on the role of the im-
mune system in DILI, but is not without limitations. The use of pe-
ripheral blood samples may not fully reflect the immune reactions 
taking place within the liver. Using liver tissue would undoubtedly 
be more informative, but would in practice be more difficult, as 
biopsies are rarely done in patients with DILI who recuperate 
without any major problems. Furthermore, the populations used 
in this study are relatively small and the results require additional 
confirmation in independent cohorts.
In conclusion, this is, to our knowledge, the first presentation 
of data on different leukocyte populations in a longitudinal study 
on acute idiosyncratic DILI and patients with additional liver 
conditions. Our data indicate an increase in activated CD4+ and 
CD8+ T- cells during the acute phase of DILI that approaches 
normal values during normalization of the liver profile. These 
data support the involvement of an adaptive immune response in 
DILI in line with previous hypotheses. A better understanding of 
the underlying mechanism of DILI will enable the development 
of specific diagnostic and prognostic biomarkers, which will fa-
cilitate clinical assessment and management of this condition.
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